KYMR · CIK 0001815442
Kymera Therapeutics, Inc.
What Kymera Therapeutics, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Kymera Therapeutics, Inc. - Profile
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
- Listed on
- Nasdaq
- Employees
- 238stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Kymera Therapeutics, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The website comes from Wikidata. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Kymera Therapeutics, Inc. Form 10-K for fiscal year 2025 and Kymera Therapeutics, Inc. Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
KYMR
Description
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Watertown, Massachusetts that develops oral medicines using targeted protein degradation, a modality that engages the cell's natural recycling system to eliminate disease-causing proteins. Its platform rests on proprietary ligands for E3 ubiquitin ligases, built into bifunctional degraders and molecular glues. The STAT6 degrader KT-621 is in the BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis and the BREADTH Phase 2b trial in moderate to severe asthma, and the IRF5 degrader KT-579 is in a Phase 1 trial in healthy volunteers. There are no approved products and all revenue is collaboration income. Under a July 2020 agreement with Sanofi covering IRAK4, the degrader KT-485/SAR447971 was dosed in a first-in-human Phase 1 trial in June 2026, earning a $20.0 million milestone, with up to $955 million of further milestones outstanding. Gilead Sciences paid $40.0 million upfront in June 2025 for an option on a CDK2 molecular glue degrader and exercised it in April 2026 over KT-200, paying $45.0 million. Collaboration revenue was $39.2 million in 2025 against a net loss of $311.4 million, and $99.4 million in the first half of 2026 against a $130.4 million loss. Cash and marketable securities were $1,505 million at 30 June 2026. Kymera had 238 full-time employees at 31 December 2025.
Who owns Kymera Therapeutics, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 250 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
250 managers reported a position, together holding 96.3m shares, or 117.1% of the company. The 40 largest are listed. Percentages are of the 82.3m shares outstanding at 24 Apr 2026, the count in force when this quarter was measured rather than the count today.
This adds up to more than the whole company, and that is what the filings say. A 13F total can exceed 100% because the same share can be reported twice: when a holder lends stock, the borrower sells it to someone else, and both the lender's manager and the new buyer's manager report it. The gap tracks how heavily a stock is shorted. It is a property of 13F rather than a fault in this data, so it is shown as filed, and it cannot be used as evidence that a particular holder's stake is large.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 501575104, held by allstate, ameriprise, bank-of-america, blackrock, blackstone, bny-mellon, capital-group, citigroup, fidelity-fmr, fifth-third, franklin-resources, geode, goldman-sachs, invesco, jpmorgan, merck, metlife, morgan-stanley, mt-bank, northern-trust, pnc, prudential-financial, raymond-james, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.